US 7,169,750 B2Granted

Methods to mobilize progenitor/stem cells

AssigneeAnorMED, Inc.

InventorsGary Bridger, Michael J. Abrams, Geoffrey W. Henson, Ronald T. MacFarland, Gary B. Calandra

Life of this patent

Estimating the term…

Loading patent…

Abstract

Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z′ (1) or pharmaceutically acceptable salt thereof wherein Z is of the formula wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1–20 atoms, Z′ is of the formula —Ar(Y)j; wherein Ar is an aromatic or heteroaromatic moiety, and each Y is independently a non-interfering substituent and j is 0–3; and “linker” represents a bond, alkylene (1–6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.

Claims21

Dependent claims

A method to obtain progenitor and/or stem cells, from a subject, which method comprises

(a) administering to said subject a compound of the formula
Z-linker-Z′ (1)
or pharmaceutically acceptable salt or prodrug form thereof
wherein Z is of the formula
wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1–20 atoms,
Z′ is of the formula
—Ar(Y)j;
wherein Ar is an aromatic or heteroaromatic moiety, and each Y is independently a non-interfering substituent and j is 0–3;
and
“linker” represents a bond, alkylene (1–6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms;
in an amount effective to mobilize said progenitor and/or stem cell population in said subject;
followed by
(b) harvesting said progenitor and/or stem cells.

10 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/456,942Filed 5 Jun 2003 · continuation in part
Priority: 31 Jul 2001
Published: US 2005/0043367 A124 Feb 2005
Granted: 30 Jan 2007
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

A61K 31/33
Medicinal preparations containing organic active ingredients: heterocyclic compounds
A61K 31/496
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed piperazines…
A61K 31/55
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/551
Having seven-membered rings, e.g. azelastine, pentylenetetrazole: having two nitrogen atoms, e.g. dilazep

Family

Application60/309,196Us provisional application · filed 31 Jul 2001
Application60/382,155Us provisional application · filed 20 May 2002
Application10/209,001Parent of this continuation-in-part · filed 30 Jul 2002
US 2005/0043367 A1Pre-grant publication · published 24 Feb 2005
US 6,987,102 B2Parent of this continuation-in-part
US 2003/0130250 A1Published application
US 7,169,750 B2This patent

From the US filing history. Foreign family members aren’t listed.